NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
12.93
-0.04 (-0.31%)
Dec 16, 2025, 4:00 PM EST - Market closed
NovoCure Revenue
NovoCure had revenue of $158.81M in the quarter ending June 30, 2025, with 5.62% growth. This brings the company's revenue in the last twelve months to $630.16M, up 14.58% year-over-year. In the year 2024, NovoCure had annual revenue of $605.22M with 18.82% growth.
Revenue (ttm)
$630.16M
Revenue Growth
+14.58%
P/S Ratio
2.22
Revenue / Employee
$431,632
Employees
1,488
Market Cap
1.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 605.22M | 95.88M | 18.82% |
| Dec 31, 2023 | 509.34M | -28.50M | -5.30% |
| Dec 31, 2022 | 537.84M | 2.81M | 0.53% |
| Dec 31, 2021 | 535.03M | 40.67M | 8.23% |
| Dec 31, 2020 | 494.37M | 143.05M | 40.72% |
| Dec 31, 2019 | 351.32M | 103.25M | 41.62% |
| Dec 31, 2018 | 248.07M | 71.04M | 40.13% |
| Dec 31, 2017 | 177.03M | 94.14M | 113.57% |
| Dec 31, 2016 | 82.89M | 49.80M | 150.52% |
| Dec 31, 2015 | 33.09M | 17.60M | 113.60% |
| Dec 31, 2014 | 15.49M | 5.13M | 49.53% |
| Dec 31, 2013 | 10.36M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
NVCR News
- 16 days ago - Novocure Appoints Company President Frank Leonard as Chief Executive Officer - Business Wire
- 21 days ago - Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference - Business Wire
- 4 weeks ago - 2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon - The Motley Fool
- 5 weeks ago - Novocure to Participate in 2025 Jefferies Global Healthcare Conference - Business Wire
- 6 weeks ago - NovoCure Limited (NVCR) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Novocure Reports Third Quarter 2025 Financial Results - Business Wire
- 2 months ago - NovoCure: Buy Rating As Pipeline Gains Drive Renewed Momentum - Seeking Alpha
- 2 months ago - Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress - Business Wire